Angeles Secord

Overview:

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Positions:

Professor of Obstetrics and Gynecology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1994

University of Washington

Resident, Obstetrics & Gynecology

Duke University

Grants:

NCI National Clinical Trials Network U10 (Year 5)

Administered By
Duke Cancer Institute
Awarded By
National Institutes of Health
Role
Co-Principal Investigator
Start Date
End Date

Women with BRCA-mutated Advanced Stage Ovarian Cancer

Administered By
Duke Clinical Research Institute
Awarded By
AstraZeneca LP
Role
Co Investigator
Start Date
End Date

Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
Gynecologic Oncology Group
Role
Investigator
Start Date
End Date

Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
American Association of Obstetricians and Gynecologists Foundation
Role
Principal Investigator
Start Date
End Date

Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer - Blood-based Angiome Profiling

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Publications:

Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.

OBJECTIVES: The COVID-19 pandemic has consumed considerable resources and has impacted the delivery of cancer care. Patients with cancer may have factors which place them at high risk for COVID 19 morbidity or mortality. Highly immunosuppressive chemotherapy regimens and possible exposure to COVID-19 during treatment may put patients at additional risk. The Society of Gynecologic Oncology convened an expert panel to address recommendations for best practices during this crisis to minimize risk to patients from deviations in cancer care and from COVID-19 morbidity. METHODS: An expert panel convened to develop initial consensus guidelines regarding anti-neoplastic therapy during the COVID-19 pandemic with respect to gynecologic cancer care and clinical trials. RESULTS: COVID-19 poses special risks to patients who are older, have medical co-morbidities, and cancer. In addition, this pandemic will likely strain resources, making delivery of cancer care or conduct of clinical trials unpredictable. Recommendations are to limit visits and contact with health care facilities by using telemedicine when appropriate, and choosing regimens which require less frequent visits and which are less immunosuppressive. Deviations will occur in clinical trials as a result of limited resources, and it is important to understand regulatory obligations to trial sponsors as well as to the IRB to ensure that clinical trial and patient safety oversight are maintained. CONCLUSIONS: The ongoing crisis will strain resources needed to deliver cancer care. When alterations to the delivery of care are mandated, efforts should be taken to minimize risks and maximize safety while approximating standard practice.
Authors
Pothuri, B; Alvarez Secord, A; Armstrong, DK; Chan, J; Fader, AN; Huh, W; Kesterson, J; Liu, JF; Moore, K; Westin, SN; Naumann, RW
MLA Citation
Pothuri, Bhavana, et al. “Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.Gynecol Oncol, vol. 158, no. 1, July 2020, pp. 16–24. Pubmed, doi:10.1016/j.ygyno.2020.04.694.
URI
https://scholars.duke.edu/individual/pub1441285
PMID
32386911
Source
pubmed
Published In
Gynecol Oncol
Volume
158
Published Date
Start Page
16
End Page
24
DOI
10.1016/j.ygyno.2020.04.694

What factors drive the choice of a genetic test? A prospective study of the preferences of women with ovarian cancer.

Authors
MLA Citation
Davidson, Brittany Anne, et al. “What factors drive the choice of a genetic test? A prospective study of the preferences of women with ovarian cancer.Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. e13621–e13621. Crossref, doi:10.1200/jco.2018.36.15_suppl.e13621.
URI
https://scholars.duke.edu/individual/pub1448965
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
36
Published Date
Start Page
e13621
End Page
e13621
DOI
10.1200/jco.2018.36.15_suppl.e13621

Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.

Authors
Friedlander, M; Chan, JK; Java, J; Armstrong, DK; Markman, M; Herzog, TJ; Monk, BJ; Backes, FJ; Secord, AA; Bonebrake, AJ; Rose, PG; Tewari, KS; Mannel, RS; Lentz, SS; Geller, MA; Copeland, LJ
MLA Citation
Friedlander, Michael, et al. “Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 5556–5556. Crossref, doi:10.1200/jco.2018.36.15_suppl.5556.
URI
https://scholars.duke.edu/individual/pub1452583
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
36
Published Date
Start Page
5556
End Page
5556
DOI
10.1200/jco.2018.36.15_suppl.5556

Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.

PURPOSE: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II trial, trastuzumab (T), a humanized-mAb targeting Her2/Neu, in combination with carboplatin/paclitaxel (C/P), is recognized as an alternative in treating advanced/recurrent HER2/Neu-positive USC. We report the updated survival analysis of NCT01367002. PATIENTS AND METHODS: Eligible patients had stage III to IV or recurrent disease. Participants were randomized 1:1 to receive C/P for six cycles ± T followed by maintenance T until progression or toxicity. Progression-free survival (PFS) was the primary endpoint; overall survival (OS) and toxicity were secondary endpoints. RESULTS: Sixty-one patients were randomized. After a median-follow-up of 25.9 months, 43 progressions and 38 deaths occurred among 58 evaluable patients. Updated median-PFS continued to favor the T-arm, with medians of 8.0 months versus 12.9 months in the control and T-arms (HR = 0.46; 90% CI, 0.28-0.76; P = 0.005). Median-PFS was 9.3 months versus 17.7 months among 41 patients with stage III to IV disease undergoing primary treatment (HR = 0.44; 90% CI, 0.23-0.83; P = 0.015), and 7.0 months versus 9.2 months among 17 patients with recurrent disease (HR = 0.12; 90% CI, 0.03-0.48; P = 0.004). OS was higher in the T compared with the control arm, with medians of 29.6 months versus 24.4 months (HR = 0.58; 90% CI, 0.34-0.99; P = 0.046). The benefit was most notable in those with stage III to IV disease, with survival median not reached in the T-arm versus 24.4 months in the control arm (HR = 0.49; 90% CI, 0.25-0.97; P = 0.041). Toxicity was not different between arms. CONCLUSIONS: Addition of T to C/P increased PFS and OS in women with advanced/recurrent HER2/Neu-positive USC, with the greatest benefit seen for the treatment of stage III to IV disease.
Authors
Fader, AN; Roque, DM; Siegel, E; Buza, N; Hui, P; Abdelghany, O; Chambers, S; Secord, AA; Havrilesky, L; O'Malley, DM; Backes, FJ; Nevadunsky, N; Edraki, B; Pikaart, D; Lowery, W; ElSahwi, K; Celano, P; Bellone, S; Azodi, M; Litkouhi, B; Ratner, E; Silasi, D-A; Schwartz, PE; Santin, AD
URI
https://scholars.duke.edu/individual/pub1450925
PMID
32601075
Source
pubmed
Published In
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Volume
26
Published Date
Start Page
3928
End Page
3935
DOI
10.1158/1078-0432.CCR-20-0953

Durable response to hormonal therapy in a patient with rapidly progressive low-grade serous ovarian cancer: A case report.

This case report describes a 46-year-old patient with rapidly progressive stage IIIA1 estrogen receptor positive low grade serous ovarian cancer (LGSC). She was optimally debulked with no residual disease and received three cycles of adjuvant liposomal doxorubicin and carboplatin intravenous chemotherapy. CT scan and pelvic exam after her third cycle revealed a 5.7 cm nodular fixed left vaginal cuff mass involving the rectosigmoid consistent with rapidly progressive disease on chemotherapy. The decision was made to initiate letrozole, and she demonstrated a prolonged partial response for 34 months on hormonal therapy. The optimal management of newly diagnosed LGSC has yet to be determined. This unique case suggests that patients with newly diagnosed disease will not be compromised if treated with adjuvant hormonal monotherapy.
Authors
Watson, CH; Secord, AA
MLA Citation
Watson, Catherine H., and Angeles Alvarez Secord. “Durable response to hormonal therapy in a patient with rapidly progressive low-grade serous ovarian cancer: A case report.Gynecol Oncol Rep, vol. 33, Aug. 2020, p. 100598. Pubmed, doi:10.1016/j.gore.2020.100598.
URI
https://scholars.duke.edu/individual/pub1452354
PMID
32685650
Source
pubmed
Published In
Gynecologic Oncology Reports
Volume
33
Published Date
Start Page
100598
DOI
10.1016/j.gore.2020.100598